In a phase 2 clinical trial, it has shown therapeutic activity in relapsing-remitting MS patients, significantly reducing brain lesions and demonstrating encouraging results in reducing confirmed ...

In a phase 2 clinical trial, it has shown therapeutic activity in relapsing-remitting MS patients, significantly reducing brain lesions and demonstrating encouraging results in reducing confirmed ...

The brain isn’t the only place where MS lesions can develop — the disease can also attack the spinal cord, ... In relapsing-remitting MS, ... This leads to inflammation and scarring. [2] ...

Multiple Sclerosis, the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. The r ...

Multiple Sclerosis MS is an autoimmune condition that can remain undetected for years A doctor explains how long MS can stay ...

In most patients (85%), the illness starts as relapsing–remitting multiple sclerosis (RRMS), characterized by episodes of neurological symptoms separated by months to years of remission.

Dr. Susan Payrovi and Dr. Mirla Avila have an in-depth discussion around treating MS, and considerations when selecting an MS ...

As most relapsing–remitting MS occurs in young adults, the occurrence at extremes of age should be disquieting, though not necessarily incorrect. Similarly, the lack of dissemination in time or ...

When it's time to talk with your doctor about primary progressive multiple sclerosis (PPMS), you may not know where to begin. Discover 11 important questions you can ask to get the conversation ...

Vidofludimus calcium is currently being evaluated in phase 3 clinical trials for the treatment of relapsing MS. In a phase 2 clinical trial, it has shown therapeutic activity in relapsing-remitting MS ...

In people with benign MS, there is a loss of overall brain tissue but other parts of the brain may grow to help compensate ...

A new study from UCLA Health has uncovered how inflammation in brain blood vessels exacerbates damage in vascular dementia ...